Lu Lin, Xu Aoshuang, Gao Fei, Tian Chenjun, Wang Honglin, Zhang Jiayao, Xie Yi, Liu Pengran, Liu Songxiang, Yang Cao, Ye Zhewei, Wu Xinghuo
Department of Orthopaedics Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cell Dev Biol. 2022 Jan 24;9:770510. doi: 10.3389/fcell.2021.770510. eCollection 2021.
Intervertebral disc degeneration (IVDD) has been reported to be the most prevalent contributor to low back pain, posing a significant strain on the healthcare systems on a global scale. Currently, there are no approved therapies available for the prevention of the progressive degeneration of intervertebral disc (IVD); however, emerging regenerative strategies that aim to restore the normal structure of the disc have been fundamentally promising. In the last decade, mesenchymal stem cells (MSCs) have received a significant deal of interest for the treatment of IVDD due to their differentiation potential, immunoregulatory capabilities, and capability to be cultured and regulated in a favorable environment. Recent investigations show that the pleiotropic impacts of MSCs are regulated by the production of soluble paracrine factors. Exosomes play an important role in regulating such effects. In this review, we have summarized the current treatments for disc degenerative diseases and their limitations and highlighted the therapeutic role and its underlying mechanism of MSC-derived exosomes in IVDD, as well as the possible future developments for exosomes.
据报道，椎间盘退变（IVDD）是导致腰痛最常见的原因，给全球医疗系统带来了巨大压力。目前，尚无经批准的疗法可用于预防椎间盘（IVD）的进行性退变；然而，旨在恢复椎间盘正常结构的新兴再生策略已显示出根本上的前景。在过去十年中，间充质干细胞（MSCs）因其分化潜能、免疫调节能力以及在适宜环境中培养和调控的能力，在IVDD治疗方面受到了广泛关注。最近的研究表明，MSCs的多效性影响是由可溶性旁分泌因子的产生所调节的。外泌体在调节这些效应中起重要作用。在本综述中，我们总结了目前针对椎间盘退行性疾病的治疗方法及其局限性，并强调了MSC来源的外泌体在IVDD中的治疗作用及其潜在机制，以及外泌体未来可能的发展方向。
Zotero 插件